Cura da Enxaqueca: a Perspectiva do Paciente
DOI:
https://doi.org/10.48208/HeadacheMed.2021.37Palavras-chave:
crença, cura, cefaleia, enxaqueca, pesquisaResumo
Objective
To conduct a web-based survey concerning patient’s perspective in the migraine cure.
Material and Methods
A total of 1,102 patients fitting the International Classification of Headache Disorders (ICHD-3) migraine criteria, seeking medical care at the Brain Research Institute at Albert Einstein Hospital in Sao Paulo, Brazil, from January to December 2015, participated in the survey. The online-based survey was accessed via the institute’s website and consisted of demographic data, a description of migraine symptoms, diagnosis and treatment, and the patient’s opinion of migraine cure and which treatment they would consider taking.
Results
Migraine intensity was significantly higher in female participants than male participants. Chronic migraine tended to affect female participants more than male participants. There was a significant difference in the rate of migraine cure belief between patients with episodic and chronic migraine.
Conclusion
Some points that were important to migraineurs have been identified in this study. Ultimately, the findings of this study may facilitate the migraine treatment decision process, by providing a better understanding of patients’ perspectives and beliefs, thus creating a more friendly communication between migraineurs and care providers and hopefully, improving the quality of life of patients.
Downloads
Referências
Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33(9):629-808 Doi:10.1177/0333102413485658 DOI: https://doi.org/10.1177/0333102413485658
Woldeamanuel YW and Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci 2017;372(307-315 Doi:10.1016/j.jns.2016.11.071 DOI: https://doi.org/10.1016/j.jns.2016.11.071
Burch R, Rizzoli P and Loder E. The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. Headache 2018;58(4):496-505 Doi:10.1111/head.13281 DOI: https://doi.org/10.1111/head.13281
Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386(9995):743-800 Doi:10.1016/S0140-6736(15)60692-4 DOI: https://doi.org/10.1016/S0140-6736(15)60692-4
Vo P, Wen S, Martel MJ, Mitsikostas D, Reuter U and Klatt J. Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. Cephalalgia 2018;333102418801579 Doi:10.1177/0333102418801579 DOI: https://doi.org/10.1177/0333102418801579
Krymchantowski AV, Silva MT, Barbosa JS and Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 2002;42(6):510-514, https://www.ncbi.nlm.nih.gov/pubmed/12167139 DOI: https://doi.org/10.1046/j.1526-4610.2002.02125.x
Bigal ME, Rapoport AM and Hargreaves R. Advances in the pharmacologic treatment of tension-type headache. Curr Pain Headache Rep 2008;12(6):442-446, https://www.ncbi.nlm.nih.gov/pubmed/18973738 DOI: https://doi.org/10.1007/s11916-008-0075-5
Silberstein SD, Feliu AL, Rupnow MF, Blount AC and Boccuzzi SJ. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache 2007;47(4):500-510 Doi:10.1111/j.1526-4610.2007.00754.x DOI: https://doi.org/10.1111/j.1526-4610.2007.00754.x
Spira PJ, Beran RG and Australian Gabapentin Chronic Daily Headache G. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 2003;61(12):1753-1759, https://www.ncbi.nlm.nih.gov/pubmed/14694042 DOI: https://doi.org/10.1212/01.WNL.0000100121.58594.11
Saper JR, Lake AE, 3rd, Cantrell DT, Winner PK and White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002;42(6):470-482, https://www.ncbi.nlm.nih.gov/pubmed/12167135 DOI: https://doi.org/10.1046/j.1526-4610.2002.02122.x
Saper JR, Silberstein SD, Lake AE, 3rd and Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994;34(9):497-502, https://www.ncbi.nlm.nih.gov/pubmed/8002320 DOI: https://doi.org/10.1111/j.1526-4610.1994.hed3409497.x
Sarchielli P, Messina P, Cupini LM, Tedeschi G, Di Piero V, Livrea P, . . . Calabresi P. Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. Eur Neuropsychopharmacol 2014;24(8):1289-1297 Doi:10.1016/j.euroneuro.2014.03.010 DOI: https://doi.org/10.1016/j.euroneuro.2014.03.010
Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, . . . Sinclair A. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev 2018;6(Cd011616 Doi:10.1002/14651858.CD011616.pub2 DOI: https://doi.org/10.1002/14651858.CD011616.pub2
Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E, . . . the American Headache S. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1346-1353 Doi:10.1212/WNL.0b013e3182535d0c DOI: https://doi.org/10.1212/WNL.0b013e3182535d0c
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, . . . the American Headache S. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1337-1345 Doi:10.1212/WNL.0b013e3182535d20 DOI: https://doi.org/10.1212/WNL.0b013e3182535d20
Ramacciotti AS, Soares BG and Atallah AN. Dipyrone for acute primary headaches. Cochrane Database Syst Rev 2007;2):CD004842 Doi:10.1002/14651858.CD004842.pub2 DOI: https://doi.org/10.1002/14651858.CD004842.pub2
Dahlof C and Maassen Van Den Brink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache 2012;52(4):707-714 Doi:10.1111/j.1526-4610.2012.02124.x DOI: https://doi.org/10.1111/j.1526-4610.2012.02124.x
Diener HC, Charles A, Goadsby PJ and Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol 2015;14(10):1010-1022 Doi:10.1016/S1474-4422(15)00198-2 DOI: https://doi.org/10.1016/S1474-4422(15)00198-2
Smitherman TA, Wells RE and Ford SG. Emerging behavioral treatments for migraine. Curr Pain Headache Rep 2015;19(4):13 Doi:10.1007/s11916-015-0486-z DOI: https://doi.org/10.1007/s11916-015-0486-z
Puledda F and Shields K. Non-Pharmacological Approaches for Migraine. Neurotherapeutics 2018;15(2):336-345 Doi:10.1007/s13311-018-0623-6 DOI: https://doi.org/10.1007/s13311-018-0623-6
Wells RE, Bertisch SM, Buettner C, Phillips RS and McCarthy EP. Complementary and alternative medicine use among adults with migraines/severe headaches. Headache 2011;51(7):1087-1097 Doi:10.1111/j.1526-4610.2011.01917.x DOI: https://doi.org/10.1111/j.1526-4610.2011.01917.x
Penzien DB, Irby MB, Smitherman TA, Rains JC and Houle TT. Well-Established and Empirically Supported Behavioral Treatments for Migraine. Curr Pain Headache Rep 2015;19(7):34 Doi:10.1007/s11916-015-0500-5 DOI: https://doi.org/10.1007/s11916-015-0500-5
Powers SW, Kashikar-Zuck SM, Allen JR, LeCates SL, Slater SK, Zafar M, . . . Hershey AD. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA 2013;310(24):2622-2630 Doi:10.1001/jama.2013.282533 DOI: https://doi.org/10.1001/jama.2013.282533
Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Vertosick EA, . . . White AR. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev 2016;6):Cd001218 Doi:10.1002/14651858.CD001218.pub3 DOI: https://doi.org/10.1002/14651858.CD007587.pub2
Wachholtz AB, Malone CD and Pargament KI. Effect of Different Meditation Types on Migraine Headache Medication Use. Behav Med 2017;43(1):1-8 Doi:10.1080/08964289.2015.1024601 DOI: https://doi.org/10.1080/08964289.2015.1024601
Keller A, Meyer B, Wohlbier HG, Overath CH and Kropp P. Migraine and Meditation: Characteristics of Cortical Activity and Stress Coping in Migraine Patients, Meditators and Healthy Controls-An Exploratory Cross-Sectional Study. Appl Psychophysiol Biofeedback 2016;41(3):307-313 Doi:10.1007/s10484-016-9334-0 DOI: https://doi.org/10.1007/s10484-016-9334-0
Schwedt TJ. Preventive Therapy of Migraine. Continuum (Minneap Minn) 2018;24(4, Headache):1052-1065 Doi:10.1212/con.0000000000000635 DOI: https://doi.org/10.1212/CON.0000000000000635
McCracken LM and Vowles KE. Acceptance and commitment therapy and mindfulness for chronic pain: model, process, and progress. Am Psychol 2014;69(2):178-187 Doi:10.1037/a0035623 DOI: https://doi.org/10.1037/a0035623
Andrasik F, Grazzi L, D'Amico D, Sansone E, Leonardi M, Raggi A and Salgado-Garcia F. Mindfulness and headache: A "new" old treatment, with new findings. Cephalalgia 2016;36(12):1192-1205 Doi:10.1177/0333102416667023 DOI: https://doi.org/10.1177/0333102416667023
Friedman BW, Lian J, Irizarry E, Mayat S, Rosa K, Bijur PE and Gallagher EJ. A qualitative analysis of the needs and expectations of patients who present to the emergency department for management of migraine. Am J Emerg Med 2018;36(7):1314-1315 Doi:10.1016/j.ajem.2017.11.039 DOI: https://doi.org/10.1016/j.ajem.2017.11.039
Becker WJ. Acute Migraine Treatment in Adults. Headache 2015;55(6):778-793 Doi:10.1111/head.12550 DOI: https://doi.org/10.1111/head.12550
Marmura MJ, Silberstein SD and Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 2015;55(1):3-20 Doi:10.1111/head.12499 DOI: https://doi.org/10.1111/head.12499
Brandes JL. Migraine in women. Continuum (Minneap Minn) 2012;18(4):835-852 Doi:10.1212/01.con.0000418646.70149.71 DOI: https://doi.org/10.1212/01.CON.0000418646.70149.71
Nappi RE and Nappi G. Neuroendocrine aspects of migraine in women. Gynecol Endocrinol 2012;28 Suppl 1(37-41 Doi:10.3109/09513590.2012.651931 DOI: https://doi.org/10.3109/09513590.2012.651931
Sumelahti ML. [Woman, hormones and migraine]. Duodecim 2013;129(4):345-350,
Silberstein SD and Hutchinson SL. Diagnosis and treatment of the menstrual migraine patient. Headache 2008;48 Suppl 3(S115-123 Doi:10.1111/j.1526-4610.2008.01309.x DOI: https://doi.org/10.1111/j.1526-4610.2008.01309.x
Rothrock JF. Menstrual migraine. Headache 2009;49(9):1399-1400 Doi:10.1111/j.1526-4610.2009.01527.x DOI: https://doi.org/10.1111/j.1526-4610.2009.01527.x
Pakalnis A. Migraine and Hormones. Semin Pediatr Neurol 2016;23(1):92-94 Doi:10.1016/j.spen.2016.01.005 DOI: https://doi.org/10.1016/j.spen.2016.01.005
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Mario Fernando Prieto Peres, Alexandre Serafim, Arão Belitardo de Oliveira, Juliane Prieto Peres Mercante
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
